TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015
The Institute was proposing that the guidance should be transferred to the ‘static guidance list’.
After consideration of all of the comments received during the review consultation, the technology appraisals programme has decided to proceed with this proposal.
Consequently, TA274 will be transferred to the ‘static guidance list’. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: 07 April 2015